NCT00669435

Losartan and Simvastatin in Hypertensive Obeses With Liver Steatosis

Ultrasonographic Modification of Liver Steatosis and Visceral Fat Induced by Treatment With Losartan and Simvastatin in Hypertensive Normocholesterolemic Obese Patients

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 75 (estimated)
• Sponsor: University of Pavia · Academic / Other
• Sex: All
• Age: 40 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

Angiotensin II has been proposed as a lipid metabolism regulator. It is known that adipocytes secrete a variety of protein, such as TNFα, plasminogen activator inhibitor (PAI)-1, leptin, resistin and adiponectin; these proteins have a wide range of biological effects and are associated with insulin resistance. Adipocytes also produce angiotensinogen and angiotensin II and a local renin-angiotensin system (RAS) is present in adipose tissue. In overweight or obese hypertensive normocholesterolemic patients the treatment with AT1-receptor blocker (Losartan) may have a better effect on hepatic steatosis and visceral fat deposition than the antihypertensive treatment with calcium channel blocker (amlodipine). Simvastatin will be added to both groups. The aim of this study is to evaluate the effect of losartan and simvastatin on ultrasonographic qualitative and quantitative parameters in overweight or obese hypertensive normocholesterolemic patients with hepatic steatosis.

Conditions

• Hypertension

Interventions

Type	Name	Description
DRUG	Losartan + Simvastatin	tablets; 50, 100 mg; od; 12 months tablets; 20 mg; od; 6 months
DRUG	Amlodipine + Simvastatin	tablets; 5, 10 mg; od; 12 months tablets; 20 mg; od; 6 months

Timeline

• Start date: 2008-04-01
• Primary completion: 2008-04-01
• Completion: 2009-04-01
• First posted: 2008-04-30
• Last updated: 2008-04-30

Locations

1 site across 1 country: Italy